Clinical trial Recruiting at 1 site Observational Ages 18 and up Women only

Investigating key epigenetic factors in breast cancer patients

Official title: "Investigating The Role of Key Non-coding RNA(s) in Breast Cancer Patients and Their Possible Crosstalk With Chromatin Remodeling Machinery"

Run by Ain Shams University · NCT06759714 · Data updated 2026-11-12

This study is trying to see if certain genetic markers in newly diagnosed breast cancer patients can help improve how doctors diagnose and treat the disease.

More Breast Cancer trials

Quick facts

Study typeObservational
Ages18 Years and up
SexWomen only
Enrollment100 (estimated)
SponsorAin Shams University
Academic / other
Locations1 site (Cairo)
StatusRecruiting
StartedNovember 23, 2024
Main results expectedMay 2025
Study endsDecember 2025
Registry record updatedJanuary 6, 2025
Trial IDNCT06759714 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are Egyptian females aged 18 years and above who have been newly diagnosed with breast cancer.

Probably not a fit

Patients with blood diseases, other cancers, liver cirrhosis, or evidence of distant metastases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on understanding the role of epigenetic regulators, specifically non-coding RNAs, in breast cancer. It aims to measure the expression levels of UPK1A-AS1 and UNC5B-AS1 in clinical samples from newly diagnosed breast cancer patients. By analyzing these molecular markers, the study seeks to enhance the diagnosis and prognosis of breast cancer, potentially leading to new therapeutic targets. The research highlights the significance of epigenetic dysregulation in cancer and its implications for patient outcomes.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnostic and prognostic tools for breast cancer patients.

How similar studies have gone: While this study explores a novel approach, previous research has indicated the potential of epigenetic markers in cancer diagnosis and prognosis.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria: Egyptian females breast cancer patients aged 18 years and above, newly diagnosed with breast cancer.

Exclusion Criteria: Blood diseases, any cancer other than breast cancer, liver cirrhosis and uterine and urinary bladder diseases or breast cancer patients with any evidence of distant metastases.

Where it's running

  • Faculty of pharmacy, Ain Shams University
    Cairo, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.